Do something amazing and help us investigate malaria

If you are aged 18 to 45 years old, in good health and live in the Thames Valley, then you may be eligible to take part in the BIO-004 study.

The total study duration is 20 months.


Study Title: NIV001

NIV001: A phase I safety and immunogenicity trial of a Nipah virus vaccine, ChAdOx1 NipahB, in healthy volunteers aged 18-55 years in the UK

The 6-in-1 Part 2 Vaccine Study


The 6-in-1 Part 2 Vaccine Study


Recruiting now for The 6-in-1 Part 2 Vaccine Study. Oxford Vaccine Group, University of Oxford would like to invite your child to take part in a study to help guide future changes to the UK immunisation schedule. We want to enroll healthy children, who have not yet received their 12-month routine vaccinations.



You are invited to take part in a challenge study to investigate whether a novel vaccine can prevent malaria. The study is being run by the Oxford Vaccine Group in partnership with the Department of Biochemistry which is part of the University of Oxford and is funded by PATH.


A Phase 2b, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess Protection Against Colonization Following Challenge with Virulent Wild-Type Bordetella pertussis (CHAMPION-1 study)

In this study, we are trying to find out how we can best protect people against pertussis (more commonly known as whooping cough). Pertussis is a highly contagious infection of the lungs and airways, caused by bacteria (small organisms which can reproduce and cause illness) called Bordetella pertussis (B. pertussis). The groups of people most severely affected by pertussis are babies, the elderly, people with chronic medical conditions that affect the lungs and heart, and people who are immunocompromised (unable to respond normally to an infection).


The Oxford Vaccine Group is recruiting infants aged 4 – 7 months to a type 1 diabetes prevention trial. POInT (Primary Oral Insulin Trial) is recruiting infants who were screened for diabetes at birth through the INGR1D Study and have been found to be at high risk for developing diabetes.